EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intensified Upadacitinib Dosing for Adolescent Patients with Acute Severe Ulcerative Colitis

Perseus V Patel iD, Martina Rigmaiden, Alka Goyal, Rachel Bensen, Dorsey Bass, Jonathan Moses iD, Michael J Rosen iD, Ruben J Colman iD

Children · 22.03.2025 · 12 (4) · 401

DOI: 10.3390/children12040401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Children, online erschienen am 22.03.2025. Verfasst von Perseus V Patel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology, Department of Pediatrics, Stanford Medicine Children's Health, Center for IBD and Celiac Disease, Stanford Un…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: In adolescent patients with ulcerative colitis refractory to anti-tumor necrosis factor (TNF) therapy, episodes of acute severe ulcerative colitis (ASUC) require hospitalization or surgery. Upadacitinib can be a potential colectomy-sparing agent in adult ASUC patients receiving intensified dosing.

Methods

This case series evaluates clinical outcomes of intensified rescue upadacitinib dosing in adolescent patients with ASUC. We included adolescents admitted with anti-TNF refractory ASUC treated with 30 mg twice daily upadacitinib. The primary outcome was the proportion of patients who remained colectomy-free at the most recent follow-up.

Results

Five patients (aged 14–18) exhibited varying responses to upadacitinib; 2 responded rapidly, while 3 had partial response. All the patients remained on upadacitinib and were colectomy-free during follow-up (55–203 days). Three (60%) ultimately received dual advanced therapy with ustekinumab and upadacitinib. At most recent follow-up, 60% were in clinical/biochemical remission without corticosteroids.

Conclusions

In select cases, intensified upadacitinib may be a potential colectomy-sparing option for adolescent ASUC patients refractory to anti-TNF therapy.

Schlagwörter

Stichwörter der Autor:innen

childreninflammatory bowel diseasejanus-kinase inhibitorpediatrictargeted small-molecule therapy

Autor:innen und Institutionen

  • Division of Pediatric Gastroenterology, Department of Pediatrics, Stanford Medicine Children's Health, Center for IBD and Celiac Disease, Stanford University School of Medicine, Palo Alto, CA 94304, USA.

ORCID-Profile: Perseus V Patel, Jonathan Moses, Michael J Rosen, Ruben J Colman

Zitieren

APA

Patel, P. V., Rigmaiden, M., Goyal, A., Bensen, R., Bass, D., Moses, J., Rosen, M. J., & Colman, R. J. (2025). Intensified Upadacitinib Dosing for Adolescent Patients with Acute Severe Ulcerative Colitis. Children, 12(4), 401. https://doi.org/10.3390/children12040401

Vancouver

Patel PV, Rigmaiden M, Goyal A, Bensen R, Bass D, Moses J, et al. Intensified Upadacitinib Dosing for Adolescent Patients with Acute Severe Ulcerative Colitis. Children. 2025;12(4):401. doi:10.3390/children12040401

BibTeX
@article{Patel2025,
  author = {Patel, Perseus V and Rigmaiden, Martina and Goyal, Alka and Bensen, Rachel and Bass, Dorsey and Moses, Jonathan and Rosen, Michael J and Colman, Ruben J},
  title = {Intensified Upadacitinib Dosing for Adolescent Patients with Acute Severe Ulcerative Colitis},
  journal = {Children},
  year = {2025},
  volume = {12},
  number = {4},
  pages = {401},
  doi = {10.3390/children12040401}
}
Kostenlos starten →